SCHEMBL378108

SCHEMBL378108

CCOC(=O)c1ccc(N2CCC(NC(C)=O)CC2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
MAPT P10636 2/20 0.50
HPGD P15428 2/20 0.49
HTT P42858 2/20 0.49
ALDH1A1 P00352 3/20 0.48
TSHR P16473 1/20 0.48
RAB9A P51151 2/20 0.47
TDP1 Q9NUW8 3/20 0.47
HSP90AA1 P07900 1/20 0.47
CACNA1B Q00975 1/20 0.47
APBA1 Q02410 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
LMNA P02545 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
MAOA P21397 1/20 0.47
FDFT1 P37268 1/20 0.46
NPC1 O15118 1/20 0.46
DRD2 P14416 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL377924 0.85 SMN1; SMN2 (0.53) MEN1KMT2AMAPTALDH1A1TSHR
Hydrochloric Acid SCHEMBL2514818 0.85 MEN1 (0.50) MEN1KMT2AHPGDHTTALDH1A1
SCHEMBL381643 0.84 CKS1B (0.48) MEN1KMT2AMAPTHPGDHTT
SCHEMBL378276 0.82 TDP1 (0.60) MEN1KMT2AMAPTHPGDHTT
SCHEMBL20884874 0.82 RORC (0.54) MEN1KMT2AMAPTHTTALDH1A1
SCHEMBL3457437 0.82 HPGD (0.55) MEN1KMT2AMAPTHPGDHTT
SCHEMBL458122 0.82 ALDH1A1 (0.53) MEN1KMT2AALDH1A1TSHRSMN1; SMN2
SCHEMBL2384645 0.82 EPHX2 (0.51) MEN1KMT2AMAPTHPGDALDH1A1
SCHEMBL20188098 0.82 HPGD (0.65) MEN1KMT2AMAPTHPGDHTT
SCHEMBL22015905 0.82 HPGD (0.65) MEN1KMT2AMAPTHPGDHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2408454-B1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP (CA) 2024-07-24 EP disclosed
US-11407719-B2 Anti-inflammatory agents RESVERLOGIX CORP. (CA) 2022-08-09 US disclosed
US-20210070716-A1 ANTI-INFLAMMATORY AGENTS HEPALINK (HONG KONG) LIMITED (HK) 2021-03-11 US disclosed
US-10882828-B2 Anti-inflammatory agents RESVERLOGIX CORP. (CA) 2021-01-05 US disclosed
US-20190119222-A1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2019-04-25 US disclosed
US-10131640-B2 Anti-inflammatory agents RESVERLOGIX CORP. (CA) 2018-11-20 US disclosed
CN-105859639-A NOVEL ANTI-INFLAMMATORY AGENTS 雷斯韦洛吉克斯公司 2016-08-17 CN disclosed
US-20160137613-A1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2016-05-19 US disclosed
US-9238640-B2 Anti-inflammatory agents RESVERLOGIX CORP. (CA) 2016-01-19 US disclosed
WO-2013175281-A1 USE OF SUBSTITUTED 2-PHENYL-3H-QUINAZOLIN-4-ONES AND ANALOGS FOR INHIBITING BROMODOMAIN AND EXTRA TERMINAL DOMAIN (BET) PROTEINS RVX THERAPEUTICS INC. (CA) 2013-11-28 WO disclosed
US-20130281399-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION RVX THERAPEUTICS INC. (CA) 2013-10-24 US disclosed
CN-102427813-A Novel anti-inflammatory agents RESVERLOGIX CORP 2012-04-25 CN disclosed
US-20120040954-A1 NOVEL ANTI-INFLAMMATORY AGENTS HEPALINK (HONG KONG) LIMITED (HK) 2012-02-16 US disclosed
EP-2408454-A2 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2012-01-25 EP disclosed
WO-2010106436-A2 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11407719-B2 Anti-inflammatory agents VCAM1, ICAM1, IL6 MEN1 3826/4885KMT2A 4037/4885MAPT 2112/4885
US-20160137613-A1 NOVEL ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 MEN1 3913/4885KMT2A 3826/4885MAPT 2027/4885
US-20130281399-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION PHKB, BAZ2A, EP300 MEN1 4236/4885KMT2A 199/4885MAPT 1238/4885
US-10882828-B2 Anti-inflammatory agents VCAM1, ICAM1, IL6 MEN1 3826/4885KMT2A 4037/4885MAPT 2112/4885
US-20210070716-A1 ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 MEN1 3826/4885KMT2A 4037/4885MAPT 2112/4885
US-10131640-B2 Anti-inflammatory agents VCAM1, ICAM1, IL6 MEN1 3826/4885KMT2A 4037/4885MAPT 2112/4885
US-20190119222-A1 NOVEL ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 MEN1 3913/4885KMT2A 3826/4885MAPT 2027/4885
US-20120040954-A1 NOVEL ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 MEN1 3913/4885KMT2A 3826/4885MAPT 2027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.